IRADIMED CORPORATION on Forbes' List of America's Most Successful Small-Cap Companies for 2025
IRADIMED CORPORATION on Forbes' List of America's Most Successful Small-Cap Companies for 2025
WINTER SPRINGS, Fla., Dec. 10, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD), today announced it has been ranked 24th on Forbes' list of America's Most Successful Small-Cap Companies 2025. Iradimed is a leader in the development of innovative magnetic resonance imaging ("MRI") medical devices and the only provider of a non-magnetic intravenous ("IV") infusion pump system and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.
佛羅里達州冬季泉水,2024年12月10日(全球新聞社)-- IRADIMED公司("公司")(納斯達克:IRMD),今天宣佈它在福布斯2025年美國最成功的小型上市公司名單中排名第24。IRadimed是開發創新的磁共振成像("MRI")醫療設備的領導者,也是唯一提供非磁性靜脈("IV")輸液泵系統和非磁性病人生命體徵監測系統的供應商,這些系統專爲MRI手術設計。
"We are honored to be included for the second consecutive year on Forbes' List of America's Most Successful Small-Cap Companies," said Roger Susi, President and Chief Executive Officer of the Company. "This important milestone highlights the strength of our commitment to innovation and execution, resulting in robust growth and record financial results. Additionally, it's a testament to our team's unwavering dedication to executing our strategic plan, which is building the foundation for customer and shareholder success. I am grateful for their commitment."
「我們很榮幸連續第二年被納入福布斯美國最成功的小型上市公司名單,」公司總裁兼首席執行官Roger Susi說。「這個重要的里程碑突顯了我們對創新和執行的承諾所帶來的強勁增長和創紀錄的財務業績。此外,這也證明了我們團隊對執行戰略計劃的不懈奉獻,而這一計劃正爲客戶和股東的成功奠定基礎。我對他們的承諾深表感謝。」
Iradimed was ranked 24th on the list of 100 companies, an improvement from 59th on last year's 2024 list. Forbes used data from FactSet to compile its annual list of America's Most Successful Small-Cap Companies and highlight some of the stocks that have stood out from the pack. Forbes screened 914 companies with a market value between $300 million and $2 billion. The top 100 stocks were ranked based on earnings growth, sales growth, return on equity and total stock return for the latest 12 months available and over the last five years. All data is as of November 8, 2024. To view the complete list of Forbes' America's Most Successful Small-Cap Companies: .
IRadimed在100家公司名單中排名第24,相較於去年的2024名單中的第59萬億有了提升。福布斯使用FactSet的數據編制美國最成功的小型上市公司年榜,並突出了一些在衆多股票中脫穎而出的公司。福布斯篩選了914家市值在30000萬美元到20億美元之間的公司。根據最近12個月和過去五年的收益增長、銷售增長、股本回報和股票總回報對前100的股票進行排名。所有數據截止到2024年11月8日。要查看福布斯美國最成功的小型上市公司完整名單:。
About IRADIMED CORPORATION
關於IRADIMED公司
IRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance Imaging ("MRI") compatible medical devices. We design, manufacture, market, and distribute MRI-compatible medical devices, accessories, disposables, and related services.
IRADIMED公司是開發創新的磁共振成像("MRI")兼容醫療設備的領導者。我們設計、製造、營銷和分銷MRI兼容醫療設備、配件、一次性用品及相關服務。
We are the only known provider of a non-magnetic intravenous ("IV") infusion pump system specifically designed to be safe for use during MRI procedures. We were the first to develop an infusion delivery system, eliminating many dangers and problems during MRI procedures. Standard infusion pumps contain magnetic and electronic components that can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium MRI compatible IV infusion pump system has a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts, and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe, and dependable fluid delivery before, during, and after an MRI scan, which is essential to critically ill patients who cannot be removed from their vital medications and children and infants who must generally be sedated to remain immobile during an MRI scan.
我們是唯一已知的非磁性靜脈("IV")輸液泵系統的提供者,專門設計用於MRI過程中的安全使用。我們是第一個開發輸液傳遞系統的公司,消除了MRI過程中的許多危險和問題。標準輸液泵包含磁性和電子元件,在強大的磁場下操作可能導致射頻干擾,且危險性極高。我們的專利MRidium MRI兼容IV輸液泵系統具有非磁性超聲波電機,獨特設計的非鐵金屬部件以及其他特殊功能,在各種MRI過程中安全且可預測地輸送麻醉藥和其他靜脈液體。我們的泵解決方案提供無縫的方法,使得在MRI掃描之前、期間和之後能夠準確、安全和可靠地輸送液體,這對於不能中斷關鍵藥物的重症患者以及在MRI掃描期間必須保持不動的兒童和嬰兒至關重要。
Our 3880 MRI-compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient's vital signs during various MRI procedures. The Iradimed 3880 system operates dependably in magnetic fields up to 30,000 gauss, which means it can operate virtually anywhere in the MRI scanner room. The Iradimed 3880 has a compact, lightweight design, allowing it to travel with the patient from their critical care unit to the MRI and back, resulting in increased patient safety through uninterrupted vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units. The features of the Iradimed 3880 include wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The Iradimed 3880 MRI-compatible patient vital signs monitoring system has an easy-to-use design and effectively communicates patient vital signs information to clinicians.
我們的3880 MRI兼容病人生命體徵監測系統具有非磁元件和其他特殊功能,可以在各種MRI過程中安全且準確地監測病人的生命體徵。Iradimed 3880系統在高達30,000高斯的磁場中可靠運行,這意味着它幾乎可以在MRI掃描室內的任何地方工作。Iradimed 3880設計緊湊、輕量化,能夠隨病人從危重病房轉移到MRI並返回,從而提高了病人安全性,實現了不間斷的生命體徵監測,並減少了危重病人離開危重病房的時間。Iradimed 3880的功能包括動態梯度濾波的無線ECG;使用麥斯莫醫療算法的無線SpO2;非磁性呼吸CO2;侵入性和非侵入性血壓;病人溫度,以及選配的先進多氣體麻醉劑裝置,具備持續的最小肺泡濃度測量。Iradimed 3880 MRI兼容病人生命體徵監測系統具有易於使用的設計,有效地向臨床醫生傳達病人生命體徵信息。
For more information, please visit .
欲了解更多信息,請訪問。
Forward-Looking Statements
前瞻性聲明
This release and any oral statements made regarding the subject of this release contain forward-looking statements as defined under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, that address activities that the Company assumes, plans, expects, believes, intends, projects, indicates, estimates, or anticipates (and other similar expressions) will, should, or may occur in the future are forward-looking statements, including statements relating financial guidance, future quarterly cash dividends, construction costs for the Company's new facility in Orlando, Florida, and the Company's strategic plans, objectives, and intentions. The forward-looking statements are based on management's current belief and currently available information on the outcome and timing of future events. The forward-looking statements involve risks and uncertainties, including, among others, that our business plans may change as circumstances warrant.
本發佈及針對本發佈主題的任何口頭聲明均包含根據《1933年證券法》第27A條修訂版和《1934年證券交易法》第21E條修訂版定義的前瞻性聲明。除了歷史事實的陳述之外,所有與公司假設、計劃、期望、相信、打算、預測、指示、估計或預期(及其他相似表達)相關的活動,將在未來發生的前瞻性陳述,包括與財務指引、未來季度現金分紅、公司在佛羅里達州奧蘭多的新設施的施工成本以及公司的戰略計劃、目標和意圖相關的陳述。前瞻性陳述基於管理層當前的信念和當前可用的信息,關於未來事件的結果和時間。前瞻性陳述涉及風險和不確定性,包括但不限於,公司業務計劃可能會在情況需要時發生變化。
Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made, which reflect management's current estimates, projections, expectations, or beliefs, and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to; potential disruptions in our limited supply chain for our products; the Company's ability to receive U.S. Food and Drug Administration ("FDA") 510(k) clearance for new products and product candidates; unexpected costs, delays or diversion of management's attention associated with the design, manufacturing or sale of new products; the Company's ability to implement successful sales techniques for existing and future products and evaluate the effectiveness of its sales techniques; additional actions, warnings or requests from the FDA or other regulatory bodies; our significant reliance on a limited number of products; a reduction in international distribution; actions of the FDA or other regulatory bodies that could delay, limit or suspend product development, manufacturing or sales; the effect of recalls, patient adverse events or deaths on our business; difficulties or delays in the development, production, manufacturing and marketing of new or existing products and services; and changes in laws and regulations or in the interpretation or application of laws or regulations. Additional factors that could affect the forward-looking statements can be found in the Company's annual report on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K filed with the U.S. Securities and Exchange Commission (the "SEC") and available on the SEC's website at http://www.sec.gov. All forward-looking statements are based on information available to us on the date hereof, and we assume no obligation to update forward-looking statements.
提醒讀者不要對前瞻性陳述過於依賴,前瞻性陳述僅在作出時有效,反映管理層當前的估計、預測、期望或信念,並且涉及的風險和不確定性可能導致實際結果和結果與預期有重大不同。可能影響公司未來結果的風險和不確定性包括但不限於:我們產品的有限供應鏈可能中斷;公司獲得美國食品藥品監督管理局("FDA")510(k)批准的新產品和產品候選者的能力;與新產品的設計、製造或銷售相關的意外成本、延誤或管理注意力的轉移;公司能夠實施現有和未來產品的成功銷售技巧與評估其銷售技巧的有效性;FDA或其他監管機構的額外措施、警告或請求;我們對少數產品的重大依賴;國際分銷的減少;FDA或其他監管機構採取的行動可能會延遲、限制或暫停產品開發、製造或銷售;召回、患者不良事件或死亡對我們業務的影響;新產品或現有產品和服務的開發、生產、製造和營銷的困難或延遲;以及法律法規或法律法規解釋或適用的變化。其他可能影響前瞻性陳述的因素可以在公司提交給美國證券交易委員會("SEC")的10-K年度報告、10-Q季度報告和8-K當前報告中找到,相關報告可在SEC網站http://www.sec.gov查閱。所有前瞻性陳述均基於截至本日期我們可獲得的信息,我們不承擔更新前瞻性陳述的任何義務。
Media Contact:
Jack Glenn
IRADIMED CORPORATION
(407) 677-8022
InvestorRelations@iradimed.com
媒體聯繫人:
傑克·格倫
IRadimed公司
(407) 677-8022
InvestorRelations@iradimed.com
A photo accompanying this announcement is available at
此公告的配圖可在此查看
譯文內容由第三人軟體翻譯。